Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 4/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.40 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 7/20 | 0.37 |
| ▸ | RELA | Q04206 | 2/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.34 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12734501 | 0.92 | CYP1A1 (0.40) | CYP1A1CYP1A2CYP1B1ERN1NFE2L2 | |
| SCHEMBL12739470 | 0.92 | CYP1A1 (0.45) | CYP1A1CYP1A2CYP1B1NFE2L2RELA | |
| SCHEMBL12734523 | 0.91 | HMOX1 (0.36) | RELAFFAR1 | |
| SCHEMBL12821235 | 0.88 | CYP1A1 (0.41) | CYP1A1CYP1A2CYP1B1ERN1NFE2L2 | |
| SCHEMBL12734504 | 0.88 | CYP1A1 (0.36) | CYP1A1CYP1A2CYP1B1ERN1NFE2L2 | |
| SCHEMBL12739455 | 0.85 | CYP1A1 (0.45) | CYP1A1CYP1A2CYP1B1NFE2L2RELA | |
| SCHEMBL12734380 | 0.84 | ALOX5AP (0.34) | CYP1A1CYP1A2CYP1B1ERN1NFE2L2 | |
| SCHEMBL12739352 | 0.84 | ALOX5AP (0.34) | CYP1A1CYP1A2CYP1B1ERN1NFE2L2 | |
| SCHEMBL12734506 | 0.84 | HMOX1 (0.35) | CYP1A1CYP1A2CYP1B1RELAFFAR1 | |
| SCHEMBL12734447 | 0.83 | TUBB1 (0.39) | ERN1NFE2L2FFAR1APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394294-B2 | Four-ring liquid crystal compound having lateral fluorine, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | CYP1A1 857/4885CYP1A2 650/4885CYP1B1 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.